Article
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
Blood advances - 8 Mar 2022
Middeke Jan M, Metzeler Klaus H, Röllig Christoph, Krämer Michael, Eckardt Jan-Niklas, Stasik Sebastian, Greif Philipp A, Spiekermann Karsten, Rothenberg-Thurley Maja, Krug Utz, Braess Jan, Krämer Alwin, Hochhaus Andreas, Brümmendorf Tim H, Naumann Ralph, Steffen Björn, Einsele Hermann, Schaich Markus, Burchert Andreas, Neubauer Andreas, Görlich Dennis, Sauerland Cristina, Schäfer-Eckart Kerstin, Schliemann Christoph, Krause Stefan W, Hänel Mathias, Frickhofen Norbert, Noppeney Richard, Kaiser Ulrich, Kaufmann Martin, Kunadt Desiree, Wörmann Bernhard, Sockel Katja, von Bonin Malte, Herold Tobias, Müller-Tidow Carsten, Platzbecker Uwe, Berdel Wolfgang E, Serve Hubert, Baldus Claudia D, Ehninger Gerhard, Schetelig Johannes, Hiddemann Wolfgang, Bornhäuser Martin, Stölzel Friedrich, Thiede Christian
Abstract excerpt
Mutations of the isocitrate dehydrogenase-1 (IDH1) and IDH2 genes are among the most frequent alterations in acute myeloid leukemia (AML) and can be found in ∼20% of patients at diagnosis. Among 4930 patients (median age, 56 years; interquartile range, 45-66) with newly diagnosed, intensively treated AML, we identified IDH1 mutations in 423 (8.6%) and IDH2 mutations in 575 (11.7%). Overall, there were no...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.